减重赛道已经是“人满为患”——老牌外资“双雄”诺和诺德的司美格鲁肽以及礼来的替尔泊肽在中国市场打得火热,线上线下平台都在积极铺货,原料药、产能问题也都在解决;与此同时,中国药企也试图“弯道超车”,掀起下一波治疗热点。对此,专家提醒,减重药物有适应症要求,消费者最好是遵医嘱或在药师指导下使用。到底应该如何评价市面上层出不穷的减重药物?复旦大学附属中山医院内分泌科主任医师、教授李小英表示,评价一款减重...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.